Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

b interferon-free trial of PSI-7977 and/or PSI-938 in patients with all HCV genotypes. Mericitabine (RG7128) continues in development through a strategic collaboration with Roche.

   Contact
       Richard E. T. Smith, Ph.D.
       VP, Investor Relations and Corporate Communications
       Office +1 (609) 865-0693

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SANTA ANA, Calif. , March 2, 2015 ... premier supplier of child-resistant packaging solutions for ... Co-Founder, Nicholas Kovacevich , has been nominated ... The Excellence in Entrepreneurship Award is ... entrepreneurial spirit – individuals who, by their creativity ...
(Date:3/2/2015)... NEW YORK , March 2, 2015 /PRNewswire/ ... LLC is investigating potential claims on behalf of ... ("Vitae Pharmaceuticals" or the "Company") (NasdaqGM: VTAE -News).  ... Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Vitae ...
(Date:3/2/2015)... March 2, 2015  CANTEL MEDICAL CORP. (NYSE: ... Krakauer , CEO, will be presenting at the Sidoti ... The formal presentation is scheduled for 2:00 PM ET ... Hotel, New York . In addition, ... Development, will be available for separate one-on-one meetings during ...
Breaking Medicine Technology:Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN; NYSE: ... previously announced acquisition of BMP Sunstone Corporation (NASDAQ: BJGP). ... Sunstone stockholders approved the adoption of the merger agreement ... wholly owned subsidiary of sanofi-aventis, dated October 28, 2010, ...
... 2011 Delta Health Technologies® LLC ("Delta") ... Therapy Report, detailing the findings from the Delta National ... develop strategies and guidelines to ensure that homecare patients ... the homecare software industry for more than 40 years, ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2Delta National Excellence in Therapy Report Now Available 2
(Date:3/2/2015)... (PRWEB) March 02, 2015 Doctors in ... be a better predictor of outcomes for people with ... read details of the new study on the ... at the University of Eastern Piedmont followed the cases ... pleurodesis treatment for excess lung fluid. , “Persistent ...
(Date:3/2/2015)... Angeles, CA (PRWEB) March 02, 2015 ... offering gum reshaping procedures. Gum reshaping can involve one or ... or to regenerate lost gum tissue for a more even ... dark gum line treatment that can permanently lighten ... his total smile approach, which involves a personalized treatment plan ...
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... 02, 2015 New York singer/songwriter ... be delivering a plenary address entitled Finding the ... Art of Healing and Recovery at this year’s ... Healthcare Executive Summit (BHES).     , With more than ... have been recorded by some of the biggest ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Over the ... acquisitions among leading vendors seeking to expand their geographic ... market is expected to reach $6.2 billion by 2019 ... North America including the U.S. and Canada and a ... devices. However developing regions such as Asia-Pacific including China ...
Breaking Medicine News(10 mins):Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... Steven Reinberg HealthDay Reporter , THURSDAY, April 12 ... partners are having babies than ever before, a new government ... 2010 were to such couples -- a threefold increase from ... Prevention found. "It,s thought that in births outside of ...
... In a study published in Nutrition Research , ... consumption with nutrient intake, diet quality and the prevalence ... in both children and adults. Consumers of OOHN, including ... pine nuts, pistachios and walnuts), had higher intakes of ...
... April 11, 2012 -- In a scientific paper ... researchers from SomaLogic and the University of Washington in ... assay technology to tissue samples. Working with both tumor ... lung cancer (NSCLC), they identified significant expression changes in ...
... , WEDNESDAY, April 11 (HealthDay News) -- The spouses ... and stroke, a new study suggests. Researchers said the ... health of caregivers. Using the national Swedish cancer registry ... heart disease and stroke increased by 13 to 29 percent ...
... , WEDNESDAY, April 11 (HealthDay News) -- Treatment-related ... their therapy has been completed, a new study says. ... and found that more than 60 percent of them ... years after their diagnosis, and 30 percent had at ...
... , WEDNESDAY, April 11 (HealthDay News) -- ... people in the United States who lived in state-regulated ... federal report. People who live in residential care ... supportive services because they can,t live independently but generally ...
Cached Medicine News:Health News:More Unmarried Couples Having Babies: CDC 2Health News:Out-of-hand tree nut consumption associated with better diet quality in children and adults 2Health News:SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples 2Health News:Breast Cancer Treatment Side Effects May Last for Years 2